GUANGJI PHARMA.(SZ:000952) Sou Hu Cai Jing·2026-02-13 10:54Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. plans to issue up to 94,936,708 A-shares to its controlling shareholder, Changjiang Industrial Investment Group, raising a total of no more than 600 million yuan, which will improve the company's financial status and enhance its resilience against macroeconomic fluctuations [1][3] Group 1: Fundraising and Shareholding Structure - The fundraising will be used to repay loans and supplement working capital, which is expected to improve the company's financial condition [3][5] - After the issuance, Changjiang Industrial Group's shareholding will significantly increase, demonstrating the controlling shareholder's confidence in the company's long-term development [1][3] Group 2: Strategic Positioning and Industry Context - Changjiang Industrial Group is the only provincial-level industrial investment platform in Hubei, focusing on strategic emerging industries, including biomedicine [3][4] - The company aligns with Hubei's "14th Five-Year Plan," which emphasizes the development of high-end medical devices and biomedicine as key growth areas [4] Group 3: Business Structure and Competitive Advantages - Guangji Pharmaceutical is a major global supplier of Vitamin B2, with a market share of approximately 30%, and has a strong operational efficiency and cost control [5][7] - The company has a long history of technological accumulation in Vitamin B2 production, maintaining stable customer relationships and a robust supply chain [7][9] Group 4: Market Trends and Future Outlook - The Vitamin B2 market is entering a down cycle but is expected to recover as global feed demand increases and synthetic biology technology reshapes cost structures [9] - The 600 million yuan fundraising is seen as the beginning of a transformation from a traditional manufacturer to a health platform enterprise [9]